ArticleBMC cancer2026
Knowledge and attitudes toward cancer clinical trials: a multi-national cross-sectional study in the Middle East and North Africa.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClinical trials (CTs) play a crucial role in developing new cancer treatments and enhancing patient outcomes. However, being part of these trials remains low across many regions, including the middle east and north Africa region (MENA). This study aims to evaluate the knowledge and attitudes of the general population regarding cancer clinical trials and to examine determinants of limited awareness and unfavorable attitudes.
methodsA multinational cross-sectional study was conducted from March 1 to May 31, 2024, initially involving 5,528 participants, with a final sample of 5,422 respondents after data cleaning. Data was collected using a standard population-based cross-sectional survey, distributed both online via Google Forms and in-person. Convenience sampling was employed, with Countries and centers were selected based on accessibility, willingness to participate, and representation of different healthcare systems across the MENA region. Data analysis was conducted using Jamovi 2.3.28 software.
resultsOf the 5,422 responses, significant participation was observed from Egypt (22.9%) and Bahrain (20.9%). Knowledge of CTs was moderate overall, with 63.5% of participants being familiar with the concept; however, only 9.1% exhibited a high level of knowledge. Attitudes toward CT participation were largely unfavorable, with 83.8% of respondents expressing reluctance to participate, despite 77.6% indicating an interest in receiving more information about CTs. Multinomial logistic regression indicated that private and governmental employees had higher knowledge levels compared to unemployed individuals(OR = 1.65, p = 0.007, and OR = 1.87, p < 0.001, respectively). Participants with chronic illnesses and those with prior research participation also demonstrated high knowledge(OR = 2.92, p < 0.001). Attitude scores, on the other hand, were significantly correlated with age and gender (p < 0.003). Sperman's revealed a positive correlation between knowledge and attitude indicating that higher knowledge levels are associated with more favorable attitudes.
conclusionThis study provides insights into the general knowledge and attitude toward cancer clinical trials among the MENA population while identifying significant gaps in understanding and willingness to participate. The findings highlight the necessity of targeted educational interventions and public awareness campaigns to enhance knowledge about clinical trials and encourage a more favorable attitude toward participation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.